UK Government invests millions into new health data service
UK focuses on digital health research: £600m (US$764m) for new data platform according to the five recommendations of the Sudlow report.
ADVERTISEMENT
About Georg Kääb
This author has not written his bio yet.
But we are proud to say that Georg Kääb contributed 43 entries already.
Entries by Georg Kääb
Swedish TIRmed Pharma raises 4,3m€ against atopic dermatitis
TIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development. Stockholm-based TIRmed Pharma has closed this funding round, led by Sciety and its investment network, Sciety Venture Partners. The capital shall support the company’s progress toward clinical development of its novel treatment for atopic dermatitis.
Menarini and ERBC collaborate
French ERBC and Menarini Biotech from Italy forge a new strategic alliance to accelerate biopharmaceutical development.
Switzerland needs more efforts in biomedicine
In February 2025, the Federal Office of Public Health (FOPH) announced that the Masterplan in Biomedicine will be discontinued. This sends a troubling signal at a time of growing protectionism and potential trade conflicts. While other nations are actively collaborating with industry to secure the future of their pharmaceutical sectors, Switzerland is abandoning the only federal initiative aimed at improving conditions for biomedical research. The organisation scienceindustries calls for a renewed effort by the government to develop a new master plan.
Morphosys’ antibody still shining – for J&J
The case of the psoriasis antiinflammation antibody guselkumab is a story of deals and cooperation and selling and buying royalties to fuel other innovation paths. J&J is right in the middle of the game and has now full ownership while expanding the indications further.
USD410m Mega Series A for yet another GLP-1 play?
Verdiva Bio, a London-based biotech, has raised an extraordinary US$410m in its oversubscribed Series A round, making it potentially the largest Series A ever raised by a U.K.-based biotech company, according to CEO Khurem Farooq.
Qiagen joins Newborn genomic screening of NHS
The aim of this unique initiative, part of the so-called Generation Study, is to sequence the genomes of 100,000 newborns in England to enable the early detection of over 200 selected conditions and to accelerate the treatment of rare diseases.
Cradle Secures $73m Series B to Accelerate AI-Driven Protein Engineering
The Dutch-Swiss company with operations also in Zurich, Switzerland, has raised US$73m in a Series B and will continue to expand its AI research, sales, and operations teams. The new announcement comes around a year after raising €21.92m in a Series A funding round.
Agomab raises US$89m in Series D
Another strong financing round for Belgian Agomab NV. Sanofi is joining the band wagon of targeting the TGFbeta receptor.
Rentschler with double-digit investment in Germany
Rentschler Biopharma announces largest single investment in the higher double-digit range at its headquarters in Germany for construction of a new buffer media facility in Laupheim.